Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
The FDA has accepted Gilead’s new drug application with a decision expected by 19 June 2025.
The FDA has accepted Gilead’s new drug application with a decision expected by 19 June 2025.
What's Your Reaction?
